Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 18;19(4):2392.
doi: 10.3390/ijerph19042392.

Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants

Rachel Siqueira de Queiroz Simões  1   2   3 , David Rodríguez-Lázaro  2   3
Affiliations
Review

Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants

Rachel Siqueira de Queiroz Simões et al. Int J Environ Res Public Health. .

Abstract

Several coronaviruses (CoVs) have been identified as human pathogens, including the α-CoVs strains HCoV-229E and HCoV-NL63 and the β-CoVs strains HCoV-HKU1 and HCoV-OC43. SARS-CoV, MERS-CoV, and SARS-CoV-2 are also classified as β-coronavirus. New SARS-CoV-2 spike genomic variants are responsible for human-to-human and interspecies transmissibility, consequences of adaptations of strains from animals to humans. The receptor-binding domain (RBD) of SARS-CoV-2 binds to receptor ACE2 in humans and animal species with high affinity, suggesting there have been adaptive genomic variants. New genomic variants including the incorporation, replacement, or deletion of the amino acids at a variety of positions in the S protein have been documented and are associated with the emergence of new strains adapted to different hosts. Interactions between mutated residues and RBD have been demonstrated by structural modelling of variants including D614G, B.1.1.7, B1.351, P.1, P2; other genomic variants allow escape from antibodies generated by vaccines. Epidemiological and molecular tools are being used for real-time tracking of pathogen evolution and particularly new SARS-CoV-2 variants. COVID-19 vaccines obtained from classical and next-generation vaccine production platforms have entered clinicals trials. Biotechnology strategies of the first generation (attenuated and inactivated virus-CoronaVac, CoVaxin; BBIBP-CorV), second generation (replicating-incompetent vector vaccines-ChAdOx-1; Ad5-nCoV; Sputnik V; JNJ-78436735 vaccine-replicating-competent vector, protein subunits, virus-like particles-NVX-CoV2373 vaccine), and third generation (nucleic-acid vaccines-INO-4800 (DNA); mRNA-1273 and BNT 162b (RNA vaccines) have been used. Additionally, dendritic cells (LV-SMENP-DC) and artificial antigen-presenting (aAPC) cells modified with lentiviral vector have also been developed to inhibit viral activity. Recombinant vaccines against COVID-19 are continuously being applied, and new clinical trials have been tested by interchangeability studies of viral vaccines developed by classical and next-generation platforms.

Keywords: SARS-CoV-2; genomic variants; technological platforms.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Electron micrograph of a coronavirus particle obtained by negative staining of a clarified suspension of a human fecal sample (Source: Monika Barth/IOC) [3].
Figure 2
Figure 2
Phylogeny of SARS-like betacoronaviruses including SARS-CoV-2, showing 49 genomes. Adapted from Nextstrain (https://nextstrain.org/groups/blab/sars-like-cov, accessed on 8 February 2022).
Figure 3
Figure 3
Three-dimensional structure of SARS-CoV-2 spike glycoprotein with positions of amino acid changes in the B.1.1.529+BA lineage (Ὸ). Changes with phenotypic effects are indicated as light orange or cyan for insertions/deletions, while variants without documented phenotypic effects are colored in green. Adapted https://www.gisaid.org/hcov19-variants/ (accessed on 8 February 2022).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Andersen K.G., Rambaut A., Lipkin W.I., Holmes E.C., Garry R.F. The proximal origin of SARS-CoV-2. Nat. Med. 2020;26:450–455. doi: 10.1038/s41591-020-0820-9. - DOI - PMC - PubMed
    1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species severe acute respiratory syndrome related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5:536–544. doi: 10.1038/s41564-020-0695-z. - DOI - PMC - PubMed
    1. Guo Y.-R., Cao Q.-D., Hong Z.-S., Tan Y.-Y., Chen S.-D., Jin H.-J., Tan K.-S., Wang D.-Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—An update on the status. Mil. Med Res. 2020;7:11. doi: 10.1186/s40779-020-00240-0. - DOI - PMC - PubMed
    1. Barth O.M., Simões R.S.Q. Virologia Humana e Veterinária. 1st ed. Thieme Revinter Medical; Rio de Janeiro, Brazil: 2019. Vírus emergentes e reemergentes; pp. 317–324.
    1. Simões R.S.Q.S. Animal and Human Coronavirus Disease. COJ Tech. Sci. Res. 2020;2:547.

Substances

Supplementary concepts